Gitte P. Aabo is President and CEO of LEO Pharma, a Danish healthcare company founded in 1908 and owned by the LEO Foundation. The company offers care solutions to people with skin diseases in more than 100 countries and has a mission to help people achieve healthy skin.
Gitte has been with LEO Pharma since 1992 where she joined as an economist. In 2001, she took up the position as Senior Vice President for Finance and IT and joined the Executive Management team in 2005. Since 2008, Gitte has been President and CEO of LEO Pharma and has transformed LEO Pharma into a global and patient-centric dermatology company, and the world leader in topical treatment of psoriasis.
Besides her corporate responsibilities, Gitte is a member of the Board of Representatives for the Danish National Bank.
Gitte holds a Bachelor of Economy from Niels Brock Copenhagen Business College (1990), a Graduate Diploma in Business Administration (1993) and an MBA (1996) from Copenhagen Business School.
Brent Saunders is Chief Executive Officer and President of Allergan plc. He previously served as Chief Executive Officer and President of Forest Laboratories and had served as a Director of Forest since 2011.
Mr. Saunders has significant healthcare industry expertise and a proven track-record leading business transformations and integrations.
Prior to Forest, he was chief executive officer of Bausch + Lomb, a leading global eye health company, serving in this capacity from March 2010 until August 2013.
Mr. Saunders also held a number of leadership positions at Schering-Plough, including the position of president of Global Consumer Health Care and was named head of integration for the company’s merger with Merck & Co. and for Schering-Plough’s acquisition of Organon BioSciences.
Before joining Schering-Plough, Mr. Saunders was a partner and head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, he was chief risk officer at Coventry Health Care and senior vice president, Compliance, Legal and Regulatory at Home Care Corporation of America. Mr. Saunders began his career as chief compliance officer for the Thomas Jefferson University Health System.
Mr. Saunders serves on the Board of Trustees of the University of Pittsburgh. He also serves on the board of the Overlook Hospital Foundation. He is also the former Chairman of the New York chapter of the American Heart Association. He is a member of the Business Council and PhRMA.
Mr. Saunders, 45, earned his MBA from Temple University School of Business, his J.D. from Temple University School of Law and his bachelor’s degree from the University of Pittsburgh.
Mr. Berns was appointed to the role of Anacor’s President and Chief Executive Officer in 2014. He has served as a member of our Board of Directors since 2012 and has served as Chairman of our Board of Directors since 2013. From August 2012 to March 2014, Mr. Berns was a self-employed consultant to the pharmaceutical industry. From March 2006 to August 2012, Mr. Berns served as President and Chief Executive Officer, and member of the board of directors, of Allos Therapeutics, Inc., which was acquired by Spectrum Pharmaceuticals, Inc. in September 2012. From July 2005 to March 2006, Mr. Berns was a self-employed consultant to the pharmaceutical industry. From June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll and from 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company.
Mr. Berns has been a director of Cellectar Biosciences, Inc. since November 2013, Jazz Pharmaceuticals, PLC since June 2010 and of XenoPort, Inc. since 2005. Mr. Berns received a B.S. in Economics from the University of Wisconsin.
Mark Bussard, M.D., Managing Director, was, prior to founding Rock Springs Capital, most recently a vice president of T. Rowe Price Group, Inc., and T. Rowe Price Associates, Inc. He was a research analyst in the U.S. Equity Division following medical device, biotechnology, and other healthcare companies. He was a vice president and Investment Advisory Committee member of the Health Sciences Fund, New Horizons Fund, Blue Chip Growth Fund, Growth & Income Fund, and Growth Stock Fund.
Prior to joining T. Rowe Price in 2005, Mark was co-founder of Rivanna Pharmaceuticals, an early stage biotechnology firm. He earned his medical degree at the University of Virginia, where he was also a resident in general surgery and was elected into the Alpha Omega Alpha medical honor society. Mark also earned a B.A. in chemistry and biology from Williams College, and an M.B.A from the Darden Graduate School of Business Administration, where he was designated a William Michael Shermet Scholar.
Mr. Clark is President, CEO and Co-Founder of Clark Pharmaceuticals LLC. Clark Pharmaceuticals was founded in 2011. Prior to this, Mr. Clark was President of Coria Laboratories from December 2003 – September 2009. Coria was acquired by Valeant Pharmaceuticals on October 31, 2008. He was named Worldwide Chairman of Dermatology in September 2009, a role in which he served until 2011. Prior to his position with Coria, Mr. Clark was President of Galderma Laboratories. During his 16 years with Galderma, he managed the company’s dynamic growth which included the development of highly successful brands Cetaphil®, DesOwen®, MetroGel®, and Differin®. Combined he spent 34 years with Galderma Laboratories and Alcon Laboratories and was inducted into Alcon’s distinguished Hall of Fame.
Mr. Clark is a recipient of the Distinguished Service Award from the American Academy of Dermatology and is an Honorary Member of the American Academy of Dermatology.
Jim DiBiasi is known for his ability to lead diverse teams and help them succeed at decisive communications opportunities. Jim provides strategic and tactical communications counsel and coaching to top executives, scientists, and doctors at pharmaceutical, biotech, and device companies. Jim has guided scientists and executives through numerous regulatory communications, such as pre-New Drug Application and Investigational New Drug meetings and challenging advisory committee meetings. He has been instrumental in developing 3D's proprietary process and communications tools to help clients analyze their audiences and prepare for their communications in more effective ways. A gifted communicator, Jim has practical experience in front of the camera and before live audiences. He has crafted and delivered hundreds of presentations and served as a legislative lobbyist and media spokesperson for Fortune 200 companies, leading them through numerous communications crises.
Jenny Kim, M.D., Ph.D. is an Associate Professor of Medicine/Dermatology at the David Geffen School of Medicine at UCLA, Associate Director of UCLA Aesthetic Service, and Chief of Dermatology at the Greater Los Angeles Healthcare System Veterans Affairs. Dr. Kim received her M.D. and Ph.D. in Immunology from UCLA and also completed her Dermatology residency and Mohs Micrographic Surgery, lasers and cosmetic dermatology fellowship there. She has been a UCLA faculty member since 2000 where she serves as referral source for patients requiring rejuvenation for aging skin and also for patients with skin cancers.
Dr. Jenny Kim provides total skin care consultation and planning. Her philosophy is that skin must be nurtured and protected and she provides comprehensive analysis and services for healthy skin and rejuvenation.
Dr. Kim is also a renowned scientist and her research is funded by the National Institutes of Health. She studies skin as an immune organ, focusing on the innate immune responses in dermatologic diseases, including acne, superficial skin infections, skin cancers and aging. Dr. Kim’s has numerous publications and has received various awards for her research. Dr. Kim is nationally recognized and lectures extensively in the U.S. and abroad. Her focus is to bring basic bench research to clinical practice. In addition, she focuses on advancing science through multidisciplinary efforts. For her work, she received the prestigious UCLA Dean’s Recognition award.
Currently Dr. Kim serves on various committees for the American Academy of Dermatology, Society for Investigative Dermatology, American Society for Dermatologic Surgery, American College of Mohs Micrographic Surgery and Women’s Dermatologic Society. Dr. Kim is an editor for the Journal of Lasers and Cosmetic Surgery and a reviewer for the Journal of Investigative Dermatology. Dr. Kim is a frequent consultant to pharmaceutical and cosmeceutical companies and serves as a member of Scientific Advisory Board for a number of pharmaceutical companies.
Dr. Kim has been featured in the news and beauty magazines including the Wall Street Journal, Los Angeles Times, Elle, Glamour, Men’s Journal and People magazine and in various radio and television shows for her expertise.
In addition to her academic endeavors, Dr. Kim is passionate about her philanthropic work, having co-founded Camp Wonder in 2001, a camp that serves children with severe skin disorders which has served over 750 children since its inception. She is an advocate for children and women. She mentors young women in medicine and science to become leaders. She is on the board of the Women’s Dermatologic Society and is an advisory member of the Associate Dean’s Faculty Partners for Diversity Group at UCLA School of Medicine. She is also devoted to her family, including her two young daughters.
Tomas Kiselak is a Managing Director with RA Capital Management, a crossover fund manager dedicated to evidence-based investing in healthcare and life science companies. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Tomas serves as an active mentor to the firm’s large team of research associates, “We all start here as scientists who know the importance of asking the right questions and then learn to assimilate more knowledge than one might think possible so that we can recognize an elegant and robust investment thesis. Seeing our newest team members make their first confident data-driven prediction is incredibly rewarding.”
Prior to joining RA Capital, Tomas worked in research laboratories at the Harvard Medical School and later at the Koch Institute at MIT studying the role of autophagy in a diverse set of disorders, ranging from Parkinson’s disease to cancer. Tomas earned his BA in Economics and Neuroscience from Amherst College.
Keith R. Leonard, Jr. was co-Founder, President and Chief Executive Officer of KYTHERA Biopharmaceuticals, Inc. from 2005 through to acquisition by Allergan in late 2015. Prior to that, Mr. Leonard held various positions at Amgen Inc., a biotechnology company. From 2001 to 2004, Mr. Leonard served as Senior Vice President and General Manager of Amgen Europe where he was responsible for all commercial operations in 28 European countries. Prior to that role, Mr. Leonard established Amgen's presence in rheumatology with the creation of the Rheumatology Business Unit, served as Head of Information Management, and served in leadership roles in sales and marketing, engineering, operations, and finance.
Mr. Leonard serves on the board of Anacor Pharmaceuticals, Inc. and the Los Angeles Opera, and previously served on the boards of Affymax, Inc. and ARYx Therapeutics, Inc. He was formerly an active duty officer in the U.S. Navy. Mr. Leonard received a B.S. in Engineering from the University of California, Los Angeles, a B.A. in History from the University of Maryland, a M.S. in Engineering from the University of California, Berkeley, and a M.B.A. from the Anderson School of Management at the University of California, Los Angeles.
Nancy McGee, Executive Vice President, is a senior healthcare consulting and operations executive with specialized expertise in health policy, health plans, and health care delivery systems with particular interest in developing innovative new offerings designed to address payer, provider, and patient access issues.
For 20 years, Nancy has been working with life sciences companies to identify opportunities to develop comprehensive access strategies and tactical programs by analyzing healthcare policy, industry, and distribution trends. She also has experience working with national health plans and pharmacy benefit management companies to help self-insured employers understand their healthcare spend while educating their employees to become effective consumers of healthcare.
Prior to joining Avalere, Nancy held positions at Castlight Health; Manatt, Phelps & Phillips; and she was the Chief Operating Officer for Lash Group. She began her consulting career at The Lewin Group.
Nancy holds a DrPH from the University of North Carolina, Chapel Hill; an MPH from Columbia University; and has been a member of the California State Bar Association since 1995. She is a board member of the Sustainable Kidney Care Foundation.
Dr. Oro is a Professor of Dermatology and a member of the Institute for Stem Cell Biology and Regenerative Medicine and the Stanford Cancer Institute at Stanford University, and the Cancer Biology and Stem Cell graduate student programs. He trained in the medical scientist program at the Salk Institute under Ron Evans lab, working on functions of novel orphan nuclear receptors in model systems. During Dermatology residency/fellowship in Matthew Scott’s lab at Stanford, he helped solidify the link between the hedgehog pathway and human cancer. In his own lab in the Program in Epithelial Biology at Stanford, Dr. Oro has extended the original studies focusing on the role of skin stem cells to understand in tissue regeneration and carcinogenesis. He has a longstanding interest in the mechanisms of hedgehog signaling in hair follicle regeneration, and in the pathogenesis of the most common human tumor, basal cell carcinoma of the skin.
As a practicing physician, Dr. Oro led the clinical trials developing the first human hedgehog pathway inhibitor in skin cancer. His interest in the mechanisms of human skin development and early ectodermal differentiation has led to the development of Therapeutic Reprogramming, the use of in vitro human skin differentiation protocols and genome editing tools to with the goal of producing clinical grade-corrected human skin from patient-specific iPS cells.
Dr. Oro has received numerous awards including the Marion Sulzberger Memorial Award, and election to the American Society for Clinical Investigation. Dr. Oro has published over 70 peer-reviewed articles, commentaries and chapters.
Michael Rosenblum, MD, PhD, is a formally trained basic immunologist and a practicing dermatologist. He received his MD and PhD degrees from the Medical College of Wisconsin and completed his residency in Dermatology at UCSF.
After completion of his residency, Dr. Rosenblum did a post-doctoral fellowship in the laboratory of Abul Abbas at UCSF. Currently, he dedicates 85% of his time to basic research and the remaining time taking care of patients with specific inflammatory and autoimmune skin diseases. The central focus of his laboratory is to understand the fundamental mechanisms of how immune responses are regulated in peripheral tissues, and how this knowledge can be exploited for therapeutic benefit.
David Steinberg joined Jefferies as Managing Director and Senior Research Analyst covering the Specialty Pharmaceuticals sector in January 2014. Previously he was a Managing Director at Deutsche Bank (formerly Alex. Brown) for 15 years. David was one of the first analysts on Wall Street to identify Specialty Pharma as a major growth opportunity for the investment community. He has regularly been voted to the Institutional Investor "All American Research Team", including each of the seven past years. He has also been selected to the Wall Street Journal's "Best on the Street" survey for stock picking.
David's research on various topics within the global drug industry has been frequently referenced in such national publications as Barron's, The New York Times, and Fortune. David has been involved with numerous dermatology/aesthetics focused companies during his career. Selected companies he has covered include Allergan, Anacor, Collagenex, Medicis, Penederm, Perrigo and Valeant.
David received a B.A. from Colby College and an MBA from the Harvard Business School.
Diane Stroehmann was Vice President of Regulatory Affairs, Pharmacovigilance and Research Compliance at Kythera Biopharmaceuticals, Inc., where she led the successful submission and approval of Kybella in the US and Canada in addition to multiple international filings. Prior to that, Ms. Stroehmann led the Regulatory Affairs group at Medicis Pharmaceutical Corporation with a focus on medical dermatology and aesthetic products. While at Medicis, Ms. Stroehmann was involved in key product approvals in dermatology and aesthetic medicine including Solodyn®, Vanos®, Luzu®, Dysport®, and Restylane®.
Ms. Stroehmann received a B.S. in Biology from the University of Illinois Champaign-Urbana, and a M.S. in Regulatory Affairs from San Diego State University.
Patricia Walker, MD, PhD, currently serves as the President and Chief Scientific Officer of Brickell Biotech. She is also on the Supervisory Board of Directors for Merz Pharma. Dr. Walker’s professional experience includes her position as Chief Medical Officer of Kythera Biopharmaceuticals, Inc., from May 2007 until March 2013. Then, from 2004 to 2007, Dr. Walker served as Executive Vice President and Chief Science Officer at Allergan Medical (formerly known as Inamed Corporation). Prior to that experience, from 1997 to 2004, Dr. Walker held positions of increasing responsibility at Allergan Inc., a biomedical company, where she ultimately served as Vice President, Clinical Research and Development for skin care pharmaceuticals.
Over the past 10 years, Dr. Walker was involved in key product approvals in dermatology and aesthetic medicine including the development and approval of Tazorac®, Azelex®, Avage®, BOTOX® Cosmetic, Hylaform®, Captique®, JUVEDERM®, Bioenterics®, LAP-BAND®, and Inamed® Silicone gel-filled Breast Implants and Kybella. Dr. Walker received her doctor of medicine (MD) degree and her doctor of philosophy (PhD) degree in Physiology and Biophysics from the University of Iowa. Dr. Walker completed a residency in Dermatology and a research fellowship in the Dermatology Branch of the National Cancer Institute at the National Institutes of Health. Dr. Walker is a board-certified Dermatologist.
Eduardo Sanchiz Yrazu became Chief Executive Officer (CEO) in July 2011, having joined Almirall in 2004 as Chief Executive Corporate Development and Finance. He is also a member of the Board of Directors. From 1998 to 2004, he held the position of Area Executive Director for Lilly In Europe.
Prior to becoming Area Executive Director, he occupied a variety of roles at Lilly in the general management, finance, marketing, and sales departments in different countries across Europe, the United States and Latin America.
Eduardo has a Master Degree in Economics and Business Administration from Universidad de Deusto, Spain, a Master of Business Administration at Instituto de Empresa, Spain.
Advancing Innovation in Dermatology, Inc. is a registered IRS 501(c)(3) organization designated as a public charity in the United States.